Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation

Wijagkanalan, Wassana; Kawakami, Shigeru; Higuchi, Yuriko; Yamashita, Fumiyoshi; Hashida, Mitsuru

doi:10.1016/j.jconrel.2009.12.016

Cited by 54 publications

(43 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other local administration routes, including intratracheal or pulmonary administration (140), and transdermal delivery (77,141) of dendrimerbased drugs, have been demonstrated. Similar findings were obtained for the increased localization of dendrimerbased drugs at the target site and prevented RES uptake via the hepatic first-pass effect for improved bioavailability and the avoidance of side effects in agreement with previous studies of liposomal drugs given by intratracheal administration (142,143).…”

Section: Routes Of Administrationsupporting

confidence: 91%

Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations

2010

Self Cite

View full text Add to dashboard Cite

Dendrimers have well-organized high branches with a layered architecture providing a series of versatile chemical modification for various purposes. Consequently, this dendrimer nanotechnology explores a new promising class of nanoscale carriers for therapeutic drugs and imaging reagents using passive and active targeting approaches. By controlling dendritic structures, the biological fate of dendrimer/dendrimer-based drugs can be significantly altered based on their intrinsic physicochemical properties, including the hydrophilicity of the unit molecules, particle size, surface charge, and modification. Accordingly, pharmacokinetic aspects play an important role in the design and development of dendrimer systems for successful in vivo application and clinical translation. This review focuses on the recent progress regarding dendritic architectures, structure-related toxicity, and critical factors affecting the pharmacokinetics and biodistribution of dendrimer/dendrimer-based drugs. A better understanding of the basic aspects of dendritic systems and their pharmacokinetics will help to develop a rationale for the design of dendrimers for the controlled delivery of drugs and imaging reagents for therapeutic or diagnostic purposes.

show abstract

Section: Routes Of Administrationsupporting

confidence: 91%

Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations

2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, concentrations of IFNc, TNFa, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of LPS-infected mice treated with Fuc-liposome complexes were significantly lower compared to the ones treated with unmodified NF-jB ODN decoys (Higuchi et al, 2006). In another study, Wijagkanalan et al revealed that mannosylated-cationic liposomes loaded with NF-jB decoys were significantly and in high amounts deposited in lungs after intratracheal administration, demonstrating significant inflammation suppressing effects (Wijagkanalan et al, 2011).…”

Section: Currently Existing Delivery Systems For Nf-jb Decoy Odnsmentioning

confidence: 99%

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

2017

View full text Add to dashboard Cite

As a prototypical pro-inflammatory transcription factor, constitutive activation of NF-κB signaling pathway has been reported in several chronic inflammatory disorders including inflammatory bowel disease, cystic fibrosis, rheumatoid arthritis and cancer. Application of decoy oligodeoxynucleotides (ODNs) against NF-κB, as an effective molecular therapy approach, has brought about several promising outcomes in treatment of chronic inflammatory disorders. However, systematic administration of these genetic constructs is mostly hampered due to their instability, rapid degradation by nucleases and poor cellular uptake. Both chemical modification and application of delivery systems have shown to effectively overcome some of these limitations. Among different administered delivery systems, nanomaterials have gained much attention for delivering NF-κB decoy ODNs owing to their high loading capacity, targeted delivery and ease of synthesis. In this review, we highlight some of the most recently developed nanomaterial-based delivery systems for overcoming limitations associated with clinical application of these genetic constructs.

show abstract

“…formamide (Man-C4-Chol), a galactosylated cholesterol derivative, to prepare mannosylated liposomes [179]. To deliver drugs into macrophage-and/or dendritic cell in various tissues, we investigated various administration routes including intravenous [179,[192][193][194][195][196][197], intraperitoneal [198][199][200][201], and intratracheal [202,203] administration.…”

Section: Development Of Mannosylated Liposomesmentioning

confidence: 99%

Glycosylation-mediated targeting of carriers

Kawakami

Hashida

2014

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

For safe and effective therapy, drugs should be delivered selectively to their target tissues or cells at an optimal rate. Drug delivery system technology maximizes the therapeutic efficacy and minimizes unfavorable drug actions by controlling their distribution profiles. Ligand-receptor binding is a typical example of specific recognition mechanisms in the body; therefore, ligand-modified drug carriers have been developed for active targeting based on receptor-mediated endocytosis. Among the various ligands reported thus far, sugar recognition is a promising approach for active targeting because of their high affinity and expression. Glycosylation has been applied for both macromolecular and liposomal carriers for cell-selective drug targeting.Recently, the combination of ultrasound exposure and glycosylated bubble liposomes has been developed. In this review, recent advances of glycosylation-mediated targeted drug delivery systems are discussed.

show abstract

Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation

Cited by 54 publications

References 47 publications

Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations

Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

Glycosylation-mediated targeting of carriers

Contact Info

Product

Resources

About